Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease

Kenneth N. Olivier, David E. Griffith, Gina Eagle, John P. McGinnis, Liza Micioni, Keith Liu, Charles L. Daley, Kevin L. Winthrop, Stephen Ruoss, Doreen J. Addrizzo-Harris, Patrick A. Flume, Daniel Dorgan, Matthias A Salathe, Barbara A. Brown-Elliott, Renu Gupta, Richard J. Wallace

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Rationale: Lengthy,multidrug, toxic, and low-efficacy regimens limit management of pulmonary nontuberculous mycobacterial disease. Objectives: In this phase II study, we investigated the efficacy and safety of liposomal amikacin for inhalation (LAI) in treatmentrefractory pulmonary nontuberculousmycobacterial (Mycobacterium avium complex [MAC] or Mycobacterium abscessus) disease. Methods: During the double-blind phase, patients were randomly assigned to LAI (590 mg) or placebo once daily added to their multidrug regimen for 84 days. Both groups could receive open-label LAI for 84 additional days. The primary endpoint was change from baseline to Day 84 on a semiquantitative mycobacterial growth scale. Other endpoints included sputum conversion, 6-minute-walk distance, and adverse events. Measurements and Main Results: The modified intention-totreat population included 89 (LAI = 44; placebo = 45) patients. The average age of the sample was 59 years; 88% were female; 92% were white; and 80 and 59 patients completed study drug dosing during the double-blind and open-label phases, respectively. The primary endpoint was not achieved (P = 0.072); however, a greater proportion of the LAI group demonstrated at least one negative sputum culture (14 [32%] of 44 vs. 4 [9%] of 45; P = 0.006) and improvement in 6-minute-walk test (120.6 m vs. 225.0 m; P = 0.017) at Day 84. A treatment effect was seen predominantly in patients without cystic fibrosis with MAC and was sustained 1 year after LAI. Most adverse events were respiratory, and in some patients it led to drug discontinuation. Conclusions: Although the primary endpoint was not reached, LAI added to a multidrug regimen produced improvements in sputum conversion and 6-minute-walk distance versus placebo with limited systemic toxicity in patients with refractory MAC lung disease. Further research in this area is needed. Clinical trial registered with www.clinicaltrials.gov (NCT01315236).

Original languageEnglish (US)
Pages (from-to)814-823
Number of pages10
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume195
Issue number6
DOIs
StatePublished - Mar 15 2017

Fingerprint

Amikacin
Inhalation
Lung Diseases
Mycobacterium avium Complex
Sputum
Placebos
Lung
Poisons
Mycobacterium
Double-Blind Method
Cystic Fibrosis
Pharmaceutical Preparations
Clinical Trials
Safety
Growth
Research
Population

Keywords

  • Culture conversion
  • Efficacy
  • Nontuberculous mycobacteria
  • Safety

ASJC Scopus subject areas

  • Medicine(all)
  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease. / Olivier, Kenneth N.; Griffith, David E.; Eagle, Gina; McGinnis, John P.; Micioni, Liza; Liu, Keith; Daley, Charles L.; Winthrop, Kevin L.; Ruoss, Stephen; Addrizzo-Harris, Doreen J.; Flume, Patrick A.; Dorgan, Daniel; Salathe, Matthias A; Brown-Elliott, Barbara A.; Gupta, Renu; Wallace, Richard J.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 195, No. 6, 15.03.2017, p. 814-823.

Research output: Contribution to journalArticle

Olivier, KN, Griffith, DE, Eagle, G, McGinnis, JP, Micioni, L, Liu, K, Daley, CL, Winthrop, KL, Ruoss, S, Addrizzo-Harris, DJ, Flume, PA, Dorgan, D, Salathe, MA, Brown-Elliott, BA, Gupta, R & Wallace, RJ 2017, 'Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease', American Journal of Respiratory and Critical Care Medicine, vol. 195, no. 6, pp. 814-823. https://doi.org/10.1164/rccm.201604-0700OC
Olivier, Kenneth N. ; Griffith, David E. ; Eagle, Gina ; McGinnis, John P. ; Micioni, Liza ; Liu, Keith ; Daley, Charles L. ; Winthrop, Kevin L. ; Ruoss, Stephen ; Addrizzo-Harris, Doreen J. ; Flume, Patrick A. ; Dorgan, Daniel ; Salathe, Matthias A ; Brown-Elliott, Barbara A. ; Gupta, Renu ; Wallace, Richard J. / Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease. In: American Journal of Respiratory and Critical Care Medicine. 2017 ; Vol. 195, No. 6. pp. 814-823.
@article{f7cf31e239584df29cde98cd1ed5a686,
title = "Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease",
abstract = "Rationale: Lengthy,multidrug, toxic, and low-efficacy regimens limit management of pulmonary nontuberculous mycobacterial disease. Objectives: In this phase II study, we investigated the efficacy and safety of liposomal amikacin for inhalation (LAI) in treatmentrefractory pulmonary nontuberculousmycobacterial (Mycobacterium avium complex [MAC] or Mycobacterium abscessus) disease. Methods: During the double-blind phase, patients were randomly assigned to LAI (590 mg) or placebo once daily added to their multidrug regimen for 84 days. Both groups could receive open-label LAI for 84 additional days. The primary endpoint was change from baseline to Day 84 on a semiquantitative mycobacterial growth scale. Other endpoints included sputum conversion, 6-minute-walk distance, and adverse events. Measurements and Main Results: The modified intention-totreat population included 89 (LAI = 44; placebo = 45) patients. The average age of the sample was 59 years; 88{\%} were female; 92{\%} were white; and 80 and 59 patients completed study drug dosing during the double-blind and open-label phases, respectively. The primary endpoint was not achieved (P = 0.072); however, a greater proportion of the LAI group demonstrated at least one negative sputum culture (14 [32{\%}] of 44 vs. 4 [9{\%}] of 45; P = 0.006) and improvement in 6-minute-walk test (120.6 m vs. 225.0 m; P = 0.017) at Day 84. A treatment effect was seen predominantly in patients without cystic fibrosis with MAC and was sustained 1 year after LAI. Most adverse events were respiratory, and in some patients it led to drug discontinuation. Conclusions: Although the primary endpoint was not reached, LAI added to a multidrug regimen produced improvements in sputum conversion and 6-minute-walk distance versus placebo with limited systemic toxicity in patients with refractory MAC lung disease. Further research in this area is needed. Clinical trial registered with www.clinicaltrials.gov (NCT01315236).",
keywords = "Culture conversion, Efficacy, Nontuberculous mycobacteria, Safety",
author = "Olivier, {Kenneth N.} and Griffith, {David E.} and Gina Eagle and McGinnis, {John P.} and Liza Micioni and Keith Liu and Daley, {Charles L.} and Winthrop, {Kevin L.} and Stephen Ruoss and Addrizzo-Harris, {Doreen J.} and Flume, {Patrick A.} and Daniel Dorgan and Salathe, {Matthias A} and Brown-Elliott, {Barbara A.} and Renu Gupta and Wallace, {Richard J.}",
year = "2017",
month = "3",
day = "15",
doi = "10.1164/rccm.201604-0700OC",
language = "English (US)",
volume = "195",
pages = "814--823",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "6",

}

TY - JOUR

T1 - Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease

AU - Olivier, Kenneth N.

AU - Griffith, David E.

AU - Eagle, Gina

AU - McGinnis, John P.

AU - Micioni, Liza

AU - Liu, Keith

AU - Daley, Charles L.

AU - Winthrop, Kevin L.

AU - Ruoss, Stephen

AU - Addrizzo-Harris, Doreen J.

AU - Flume, Patrick A.

AU - Dorgan, Daniel

AU - Salathe, Matthias A

AU - Brown-Elliott, Barbara A.

AU - Gupta, Renu

AU - Wallace, Richard J.

PY - 2017/3/15

Y1 - 2017/3/15

N2 - Rationale: Lengthy,multidrug, toxic, and low-efficacy regimens limit management of pulmonary nontuberculous mycobacterial disease. Objectives: In this phase II study, we investigated the efficacy and safety of liposomal amikacin for inhalation (LAI) in treatmentrefractory pulmonary nontuberculousmycobacterial (Mycobacterium avium complex [MAC] or Mycobacterium abscessus) disease. Methods: During the double-blind phase, patients were randomly assigned to LAI (590 mg) or placebo once daily added to their multidrug regimen for 84 days. Both groups could receive open-label LAI for 84 additional days. The primary endpoint was change from baseline to Day 84 on a semiquantitative mycobacterial growth scale. Other endpoints included sputum conversion, 6-minute-walk distance, and adverse events. Measurements and Main Results: The modified intention-totreat population included 89 (LAI = 44; placebo = 45) patients. The average age of the sample was 59 years; 88% were female; 92% were white; and 80 and 59 patients completed study drug dosing during the double-blind and open-label phases, respectively. The primary endpoint was not achieved (P = 0.072); however, a greater proportion of the LAI group demonstrated at least one negative sputum culture (14 [32%] of 44 vs. 4 [9%] of 45; P = 0.006) and improvement in 6-minute-walk test (120.6 m vs. 225.0 m; P = 0.017) at Day 84. A treatment effect was seen predominantly in patients without cystic fibrosis with MAC and was sustained 1 year after LAI. Most adverse events were respiratory, and in some patients it led to drug discontinuation. Conclusions: Although the primary endpoint was not reached, LAI added to a multidrug regimen produced improvements in sputum conversion and 6-minute-walk distance versus placebo with limited systemic toxicity in patients with refractory MAC lung disease. Further research in this area is needed. Clinical trial registered with www.clinicaltrials.gov (NCT01315236).

AB - Rationale: Lengthy,multidrug, toxic, and low-efficacy regimens limit management of pulmonary nontuberculous mycobacterial disease. Objectives: In this phase II study, we investigated the efficacy and safety of liposomal amikacin for inhalation (LAI) in treatmentrefractory pulmonary nontuberculousmycobacterial (Mycobacterium avium complex [MAC] or Mycobacterium abscessus) disease. Methods: During the double-blind phase, patients were randomly assigned to LAI (590 mg) or placebo once daily added to their multidrug regimen for 84 days. Both groups could receive open-label LAI for 84 additional days. The primary endpoint was change from baseline to Day 84 on a semiquantitative mycobacterial growth scale. Other endpoints included sputum conversion, 6-minute-walk distance, and adverse events. Measurements and Main Results: The modified intention-totreat population included 89 (LAI = 44; placebo = 45) patients. The average age of the sample was 59 years; 88% were female; 92% were white; and 80 and 59 patients completed study drug dosing during the double-blind and open-label phases, respectively. The primary endpoint was not achieved (P = 0.072); however, a greater proportion of the LAI group demonstrated at least one negative sputum culture (14 [32%] of 44 vs. 4 [9%] of 45; P = 0.006) and improvement in 6-minute-walk test (120.6 m vs. 225.0 m; P = 0.017) at Day 84. A treatment effect was seen predominantly in patients without cystic fibrosis with MAC and was sustained 1 year after LAI. Most adverse events were respiratory, and in some patients it led to drug discontinuation. Conclusions: Although the primary endpoint was not reached, LAI added to a multidrug regimen produced improvements in sputum conversion and 6-minute-walk distance versus placebo with limited systemic toxicity in patients with refractory MAC lung disease. Further research in this area is needed. Clinical trial registered with www.clinicaltrials.gov (NCT01315236).

KW - Culture conversion

KW - Efficacy

KW - Nontuberculous mycobacteria

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=85015872577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015872577&partnerID=8YFLogxK

U2 - 10.1164/rccm.201604-0700OC

DO - 10.1164/rccm.201604-0700OC

M3 - Article

C2 - 27748623

AN - SCOPUS:85015872577

VL - 195

SP - 814

EP - 823

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 6

ER -